High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform

Table 3

Overall changes in parameters after HIFU focal therapy.

Parameters	Baseline	3 months	value^#	6 months	value
Mean PSA (ng/ml) ± SD	8.4 ± 3.3	4.2 ± 3.1	<0.001	3.7 ± 2.4	<0.001
Mean IPSS ± SD	11.2 ± 5.8	8.4 ± 5.1	0.034	8.8 ± 5.8	0.122
Mean QoL ± SD	2.4 ± 1.3	2.1 ± 1.2	0.281	2.5 ± 1.0	0.377
Mean OABSS ± SD	4.5 ± 2.6	4.2 ± 1.9	0.325	4.6 ± 2.2	0.500
Mean IIEF-5 ± SD	15.1 ± 6.5	11.7 ± 8.5	0.001	13.7 ± 7.6	0.314
Mean SF-12 ± SD
Physical score	48.4 ± 5.9	49.7 ± 7.4	0.304	49.3 ± 6.5	0.346
Mental score	47.6 ± 10.8	49.0 ± 7.7	0.339	48.3 ± 7.0	0.422
Mean EPIC-26 score ± SD
Incontinence	91.3 ± 13.7	90.0 ± 18.6	0.426	90.5 ± 15.1	0.449
LUTS	81.7 ± 15.2	86.7 ± 12.2	0.165	85.8 ± 11.7	0.204
Bowel function	87.8 ± 14.6	88.4 ± 13.3	0.456	85.1 ± 17.1	0.330
Sexual function	49.6 ± 30.5	43.3 ± 30.5	0.301	40.8 ± 31.0	0.237
Hormonal function	97.5 ± 6.6	97.2 ± 5.8	0.444	97.2 ± 4.8	0.440
Uroflowmetry
Qmax (ml/s) ± SD	14.9 ± 6.3	14.6 ± 5.2	0.451	14.4 ± 6.9	0.428
PVRU (ml)	68.6 ± 41.1	53.2 ± 48.1	0.194	47.5 ± 42.2	0.104

SD, standard deviation; PSA, prostatic specific antigen; PHI, prostate health index; IPSS, International Prostate Symptom Score; QoL, quality of life; OABSS, overactive bladder symptom score; IIEF-5, International Index of Erectile Function; SF-12, 12-item short form survey; EPIC-25, expanded prostate cancer index composite; LUTS, lower urinary tract symptoms; Qmax, maximal voiding velocity; PVRU, postvoid residual urine. ^#Comparison of 3-month data against the baseline value. Comparison of 6-month data against the baseline value.